Congress of the United States

House of Representatives

COMMITTEE ON OVERSIGHT AND GOVERNMENT REFORM 2157 RAYBURN HOUSE OFFICE BUILDING

> WASHINGTON, DC 20515–6143 MAJORITY (202) 225-5074 MINORITY (202) 225-5051 https://oversight.house.gov

MEMORANDUM

June 5, 2025

To: Members, Committee on Oversight and Government Reform

From: Committee Staff

Re: Hearing titled "Securing Americans' Genetic Information: Privacy and National Security Concerns Surrounding 23andMe's Bankruptcy Sale"

On Tuesday, June 10, 2025, at 10:00 a.m. ET, in room HVC-210 of the U.S. Capitol Visitor Center, the Committee on Oversight and Government Reform will host a hearing titled "Securing Americans' Genetic Information: Privacy and National Security Concerns Surrounding 23andMe's Bankruptcy Sale."

I. BACKGROUND:

23andMe, Inc. (23andMe) is a direct-to-consumer genetic testing company in possession of the genetic data of millions of Americans, including details about ancestry, family traits, and potential health risks. 23andMe filed for bankruptcy on March 23, 2025, and this raised serious concerns regarding potential transfers of sensitive personal data to other entities, including the Chinese Communist Party (CCP). Regeneron Pharmaceutical, Inc. (Regeneron) entered into an asset purchase agreement to acquire 23andMe on May 19, 2025. The concerns surrounding the security of Americans' genetic data are still outstanding as it is currently unknown what will happen to the data acquired from 23andMe.

II. HEARING PURPOSE:

This hearing will provide an opportunity for Members to examine the steps 23andMe has taken to ensure Americans' genetic data is safeguarded from malign foreign actors and other potential harms upon the completed sale of the company.

III. WITNESSES:

Mr. Joe Selsavage Interim CEO 23andMe, Inc.

Ms. Anne Wojcicki Board Member 23andMe, Inc.